LOC643669 Inhibitors
LOC643669 inhibitors would target specific signaling pathways or biological processes to indirectly inhibit the functional activity of LOC643669, also known as CCER2. These compounds are not inhibitors of LOC643669 in the conventional sense, but rather influence cellular pathways that CCER2 may be involved in. For instance, compounds like Rapamycin and Everolimus target the mTOR pathway, which is a central regulator of cell growth and proliferation. By inhibiting mTOR, these compounds could reduce the functional activity of CCER2 if it is involved in similar cellular processes.
Other compounds, such as LY294002 and Wortmannin, are PI3K inhibitors that would lead to decreased AKT signaling. This reduction in AKT signaling could have an inhibitory effect on CCER2 if the protein's activity is connected to the PI3K/AKT pathway. This pathway is critical in regulating various cellular functions, including metabolism, growth, proliferation, survival, and angiogenesis
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR (mechanistic target of rapamycin), which can downregulate protein synthesis and cell growth. If CCER2 is involved in cellular growth pathways, its functional activity could be indirectly decreased as a result of the general suppression of these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that leads to the inhibition of the AKT signaling pathway. Downstream effects include reduced cell survival and proliferation, which could diminish CCER2 activity if CCER2 plays a role in these cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, leading to decreased ERK phosphorylation and activity. If CCER2 function is reliant on ERK signaling for its activation or stabilization, then U0126 could result in decreased CCER2 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAPK. If CCER2 activity is modulated by p38 MAPK-dependent signaling, inhibition of p38 MAPK could result in reduced CCER2 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which affects cell proliferation and apoptosis. Inhibition of JNK signaling could lead to decreased CCER2 function if CCER2 is involved in pathways regulated by JNK. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the activation of MAPK/ERK. If CCER2 operates downstream or is regulated by the MAPK/ERK pathway, this inhibition would reduce CCER2 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that would lead to a decrease in AKT signaling. Decreased AKT signaling could lead to reduced CCER2 activity if CCER2 function is linked to the AKT pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor. If CCER2 is activated or stabilized by Src kinase signaling, then inhibiting this pathway could result in decreased CCER2 activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits multiple tyrosine kinases, including Src. Decreased Src kinase activity could lead to diminished CCER2 function if CCER2 is involved in signaling pathways that require Src kinase activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib inhibits EGFR tyrosine kinase, which could lead to a reduction in downstream signaling pathways such as MAPK, PI3K/AKT, and JNK. This could indirectly decrease CCER2 activity if it is regulated by these pathways. | ||||||